515 Results

Focal One focused ultrasound (HIFU) device secures FDA 510(k) clearance for the ablation of prostate tissue.- EDAP TMS SA.

 Added 3 days ago

EDAP TMS SA a global leader in therapeutic ultrasound, announced that it has received 510(k) clearance from the FDA for...

Sutent improves survival in renal cell carcimoma patients who can avoid surgery. Pfizer.

 Added 10 days ago

Data from the Phase III CARMENA trial evaluating Sutent (sunitinib) from Pfizer Inc. showed that patients with renal cell carcinoma...

NICE does not recommend Zytiga plus ADT and prednisone as first line therapy in metastatic prostate cancer.- Janssen.

 Added 11 days ago

The National Institute for Health and Care Excellence has published draft guidelines rejecting the use of Zytiga (abiraterone acetate), from...

Phase III trial of TRCA 301 meets primary endpoint in chronic kidney disease.- Tricida.

 Added 12 days ago

Tricida announced results from its pivotal Phase III double-blind, randomized, placebo-controlled, multi-center Phase III clinical trial, TRCA 301, in 217...

EMA warning relating to use of Keytruda and Tecentriq in bladder cancer. Merck Inc. and Roche .

 Added 13 days ago

Early data from two clinical trials ( Keynote-361 and IMvigor130 ) show reduced survival with Keytruda (pembrolizumab) and Tecentriq (atezolizumab)...

CHECKMATE 214 trial success for Opdivo + Yervoy (low dose) v. sunitinib for renal cell carcinoma.

 Added 16 days ago

Bristol-Myers Squibb Company announced patient-reported outcomes data from the Phase III CheckMate -214 trial in intermediate- and poor-risk patients with...

FDA accepts sDNA for Promacta for first line treatment of severe aplastic anemia.- Novartis.

 Added 18 days ago

Novartis has announced that the FDA has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Review designation...

FDA warning of deaths in KEYNOTE 361 and IMvigor 130 studies of patients with bladder cancer taking Keytruda or Tecentriq monotherapy. Merck Inc.and Genentech /Roche.

 Added 21 days ago

The FDA on 25 May warned oncologists and clinical trial investigators of early signs from two trials that some bladder...

Successful Phase III VISTA trial of Vicinium to treat high-grade non-muscle invasive bladder cancer . Sesen Bio.Inc.

 Added 24 days ago

Sesen Bio, Inc. (formerly Eleven Biotherapeutics) has announced positive, three-month data from its ongoing Phase III VISTA Trial of Vicinium...

Yonsa approved by the FDA for metastatic castration-resistant prostate cancer.- Sun Pharma.

 Added 25 days ago

Sun Pharmaceutical Industries Ltd and Churchill Pharmaceuticals, LLC. announced that one of Sun Pharma’s wholly owned subsidiary companies has received...

Load more